Warnings
Medetomidine
Mistenni: Bromażolam. Rilevat Medetomidina. Lokazzjoni: Australia. Data: 2025-11-27. Sors: Victorian Pill Testing Service.
Detected Substances
- Medetomidine
Expected vs Detected
Bromazolam
Detected result: Medetomidine
Sample Details
No additional sample descriptors available.
Testing Context
- Location: Australia
- Date tested: 2025-11-27
- Source: Victorian Pill Testing Service
Harm Reduction
- Similar-looking pills can contain different substances or strengths.
- Use drug checking services when available.
- Start low and avoid assuming a logo identifies the contents.
SampleDNA Beta
30 avviżi relatati · Tgħallem aktar dwar l-impuritajiet komuni.
- MedetomidineMisjub
Kampjuni relatati u kombinazzjonijiet
Medetomidine
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Xanax logo
L-istess logo jidher f'riżultati relatati tal-iċċekkjar tad-drogi.
6-MAM + Acetylcodeine + Caffeine + Heroin + Medetomidine + Noscapine + Papaverine + Paracetamol
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
- Heroin + Noscapine + Paracetamol + Acetylcodeine + Caffeine + Medetomidine + 6-MAM + Papaverine
- Caffeine + Heroin + 6-MAM + Noscapine + Paracetamol + Acetylcodeine + Medetomidine + Papaverine
- Acetylcodeine + Caffeine + Heroin + 6-MAM + Noscapine + Papaverine + Paracetamol + Medetomidine
- Caffeine + Heroin + Medetomidine + 6-MAM + Noscapine + Paracetamol + Acetylcodeine + Papaverine
- Heroin + 6-MAM + Noscapine + Papaverine + Paracetamol + Acetylcodeine + Caffeine + Medetomidine
- Heroin + Medetomidine + 6-MAM + Noscapine + Paracetamol + Acetylcodeine + Caffeine + Papaverine
6-MAM + Acetylcodeine + Caffeine + Dimethocaine + Heroin + Medetomidine + Noscapine + Papaverine + Paracetamol
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
6-MAM + Caffeine + Dimethocaine + Heroin + Medetomidine + Noscapine + Papaverine + Paracetamol
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Links
This static page is intended as the readable export baseline for crawler and low-capability delivery.
